PTN
HealthcarePalatin Technologies, Inc. · Biotechnology · $390M
What is Palatin Technologies, Inc.?
Palatin Technologies is a small-cap biopharmaceutical company focused on developing targeted, receptor-specific therapeutics. Based in Cranbury, New Jersey, the company is working across several disease areas including sexual health, inflammatory conditions, and cardiovascular disease.
Palatin generates revenue primarily through its commercialized product Vyleesi, a melanocortin receptor agonist approved for premenopausal women with hypoactive sexual desire disorder. Beyond its lead asset, the company advances an early-stage pipeline targeting inflammatory bowel disease, dry eye disease, diabetic retinopathy, and cardiovascular conditions. Its research centers on melanocortin and natriuretic peptide receptor pathways, aiming to develop novel peptide-based therapies where few treatment options currently exist.
Palatin Technologies was incorporated in 1986 and is headquartered in Cranbury, New Jersey.
- Vyleesi — approved melanocortin receptor agonist for hypoactive sexual desire disorder
- PL8177 — oral MC1r agonist in development for inflammatory bowel disease
- PL9643 — peptide agonist targeting dry eye disease and ocular inflammation
- PL3994 — natriuretic peptide receptor agonist for cardiovascular indications
- PL5028 — dual NPR-A/NPR-B candidate for cardiovascular and fibrotic diseases
Is PTN a Good Stock to Buy?
UQS Score rates PTN as Poor overall, reflecting broad weakness across most quality dimensions.
The one area where PTN stands out relative to its profile is Valuation, which is rated Attractive — suggesting the market has already priced in significant uncertainty. The Risk pillar comes in at Neutral, which is notable for a clinical-stage biopharmaceutical company carrying pipeline and commercial execution risk.
Quality, Moat, and Growth are all rated Weak, pointing to limited competitive differentiation, constrained financial health, and an unclear near-term growth trajectory for the business.
Pro members can view the complete pillar breakdown and underlying financial metrics driving the PTN score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does PTN pay dividends?
No — Palatin Technologies, Inc. does not currently pay a dividend.
Palatin Technologies does not pay a dividend. This is typical for early-stage biopharmaceutical companies, where available capital is directed toward research, clinical development, and pipeline advancement rather than shareholder distributions. Investors in PTN are generally seeking potential pipeline value rather than income.
When does PTN report earnings?
Palatin Technologies reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a small-cap biopharma with a single commercialized product and an early-stage pipeline, quarterly results tend to reflect operating expenses tied to clinical development alongside modest product revenues. Investors typically focus on pipeline milestones and cash runway rather than traditional earnings metrics.
For the most recent quarter's results and guidance, visit Palatin Technologies' investor relations page directly.
PTN Price History
-96.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Palatin Technologies, Inc.?
Based on Palatin Technologies, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
PTN Long-term Outlook
The Growth pillar for PTN is rated Weak, reflecting the challenges of scaling a single approved product while funding multiple early-stage pipeline programs. The Attractive Valuation rating suggests downside may be limited at current levels, but meaningful upside is likely contingent on clinical trial outcomes or partnership activity. The Neutral Risk rating indicates the company is not in immediate distress, though execution risk remains elevated for a business of this size and stage.
Growth drivers
- Potential commercial uptake expansion for Vyleesi in the hypoactive sexual desire disorder market
- Pipeline progression in inflammatory bowel disease and dry eye disease indications
- Possible licensing or partnership deals leveraging the melanocortin receptor platform
Key risks
- Clinical trial failure risk across multiple early-stage pipeline candidates
- Limited financial resources typical of small-cap biopharma companies
- Competitive pressure in sexual health and inflammatory disease therapeutic areas
PTN vs Peers
Palatin Technologies operates in a competitive small-cap biopharma landscape alongside other receptor-focused drug developers.
Crescent Biopharma focuses on oncology-targeted therapies, differentiating itself from Palatin's melanocortin and natriuretic peptide receptor approach.
Prothena pursues protein dysregulation diseases with a more advanced clinical pipeline, giving it a different risk and stage profile compared to PTN.
Rigel has commercialized products in hematology and oncology support, providing a more established revenue base than Palatin's single approved asset.
Frequently Asked Questions
What does Palatin Technologies do?
Palatin Technologies is a biopharmaceutical company developing receptor-specific peptide therapeutics. Its lead approved product, Vyleesi, treats hypoactive sexual desire disorder in premenopausal women. The company also has a pipeline spanning inflammatory bowel disease, dry eye disease, and cardiovascular conditions, all built around melanocortin and natriuretic peptide receptor science.
Does PTN pay dividends?
No, Palatin Technologies does not pay a dividend. Like most small-cap biopharmaceutical companies, it reinvests available capital into clinical development and pipeline programs rather than returning cash to shareholders through distributions.
When does PTN report earnings?
Palatin Technologies follows a standard quarterly reporting cadence for US-listed companies. For exact dates and the most recent financial results, check the investor relations section of the company's official website.
Is PTN a good stock to buy?
The UQS Score rates PTN as Poor overall, with Weak ratings across Quality, Moat, and Growth. The Valuation pillar is Attractive, which may reflect that risk is already priced in — but that alone does not make it suitable for every investor. The full pillar breakdown is available to Pro members.
Is PTN overvalued?
Based on the UQS Valuation pillar, PTN is rated Attractive, suggesting the stock is not considered overvalued relative to its fundamentals at current levels. However, an attractive valuation in a company with Weak Quality and Growth pillars reflects meaningful underlying risk rather than a straightforward opportunity.
How does PTN compare to its competitors?
Compared to peers like Rigel Pharmaceuticals and Prothena, Palatin is at an earlier commercial stage with a narrower approved product portfolio. Its melanocortin receptor platform is scientifically differentiated, but competitors in the small-cap biopharma space often have more advanced or diversified pipelines.
What is PTN's market cap bracket?
Palatin Technologies is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, greater sensitivity to clinical trial outcomes, and more limited access to capital compared to large- or mega-cap pharmaceutical companies.
Who founded Palatin Technologies?
Palatin Technologies was incorporated in 1986. Detailed founding history, including the names of original founders, is publicly available through the company's official filings and corporate history disclosures.
Is PTN a long-term quality investment?
As a long-term quality indicator, the UQS Score rates PTN as Poor. Weak scores across Quality, Moat, and Growth suggest the business currently lacks the durable characteristics typically associated with long-term compounders. Pipeline success could change this profile, but that outcome remains uncertain.
What is the main competitive advantage of Palatin Technologies?
Palatin's primary differentiator is its proprietary melanocortin receptor platform, which underpins both its approved product and its pipeline. This receptor-specific approach targets biological pathways with limited existing therapies, though the Moat pillar is currently rated Weak, indicating this advantage has not yet translated into durable competitive positioning.
What sector does PTN belong to?
Palatin Technologies operates in the Healthcare sector, specifically within biopharmaceuticals. It focuses on peptide-based drug development targeting receptor pathways involved in sexual health, inflammation, ocular disease, and cardiovascular conditions.
Unlock Full PTN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for PTN
- ✓Access underlying financial metrics driving each pillar
- ✓Compare PTN against sector peers on quality and risk
- ✓See the complete Growth and Moat breakdown
- ✓Track score changes as new data becomes available
Pro Analysis
PTN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | 30.1 | 0.0 | 9.0 | 18.8 | 60.7 | 100.0 | +0.2 |
| Apr 22, 2026 | 29.9 | 0.0 | 9.0 | 18.8 | 59.1 | 100.0 | -0.9 |
| Apr 2, 2026 | 30.8 | 0.0 | 9.0 | 23.5 | 59.1 | 100.0 | — |
PTN — Pillar Breakdown
Quality
— 0.0/100 (25%)Palatin Technologies, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.8/100 (20%)Palatin Technologies, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 60.7/100 (15%)Palatin Technologies, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Palatin Technologies, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 9/100 (25%)Palatin Technologies, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PTN.
Score Composition
Financial Data
More Stock Analysis
How is the PTN UQS Score Calculated?
The UQS (Unified Quality Score) for Palatin Technologies, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Palatin Technologies, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Palatin Technologies, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.